DNLI
HEALTHCAREDenali Therapeutics Inc
AI Insight
What's Moving DNLI Today?
No stock-specific AI insight has been generated for DNLI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$12.58$25.30
$24.77
Fundamentals
Market Cap$3.8B
P/E Ratio—
EPS$-2.88
Dividend Yield—
Dividend / Share—
ROE-49.6%
Profit Margin—
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding158.7M
DNLI News
24 articles- Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS IIYahoo Finance·Jun 23, 2026
- Denali to Sell Priority Review Voucher for $195M Cash BoostYahoo Finance·Jun 19, 2026
- Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 MillionYahoo Finance·Jun 18, 2026
- Pfizer CFO to step down; Denali sells a regulatory fast-passBiopharmadive·Jun 18, 2026
- Acumen Nominates 2 Therapies to Treat Alzheimer’s DiseaseYahoo Finance·Jun 16, 2026
- What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech NamesYahoo Finance·Jun 11, 2026
- Biogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration PipelineYahoo Finance·Jun 2, 2026
- Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff BezosYahoo Finance·Jun 1, 2026
- Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley SaysYahoo Finance·May 26, 2026
- Stocks Settle Higher on Iran Peace Hopes and Tech StrengthBarchart·May 22, 2026
- Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline RisksYahoo Finance·May 22, 2026
- Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study FailsYahoo Finance·May 22, 2026
- Stocks Climb on US-Iran Peace Hopes and Strength in ChipmakersBarchart·May 22, 2026
- Stocks Supported by US-Iran Peace Deal OptimismBarchart·May 22, 2026
- Parkinson’s drug from Biogen, Denali comes up shortBiopharmadive·May 22, 2026
- BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In TrialStocktwits·May 21, 2026
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s DiseaseGlobeNewswire Inc.·May 21, 2026
- Hedge Fund Wagers $36 Million on Biotech Denali After First FDA ApprovalMotley Fool·May 18, 2026
- Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome ApprovalMarketbeat·May 16, 2026
- T. Rowe Price holds 5.4% of Denali Therapeutics (NASDAQ: DNLI)Stock Titan·May 15, 2026
- Oppenheimer Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $40Moomoo·May 12, 2026
- Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'Yahoo Finance·May 9, 2026
- Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's WhyBenzinga·Apr 6, 2026
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepBenzinga·Apr 1, 2026
All 24 articles loaded
Price Data
Open$23.76
Previous Close$24.77
Day High$25.31
Day Low$23.51
52 Week High$25.30
52 Week Low$12.58
52-Week Range
$12.58$25.30
$24.77
Fundamentals
Market Cap$3.8B
P/E Ratio—
EPS$-2.88
Dividend Yield—
Dividend / Share—
ROE-49.6%
Profit Margin—
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding158.7M
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—